Annual report pursuant to Section 13 and 15(d)

Note 16 - Material Agreements (Details Textual)

v3.23.1
Note 16 - Material Agreements (Details Textual) - USD ($)
 1 Months Ended 12 Months Ended 15 Months Ended
Oct. 24, 2022
Nov. 23, 2021
Jul. 14, 2014
Jan. 31, 2002
Dec. 31, 2022
Dec. 31, 2021
Oct. 24, 2021
Research and development expenses         $ 5,969,774 $ 5,141,910  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number         537,390    
Restricted Stock [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period         35,000 70,000  
Former Chief Executive Officer [Member]              
Employment Agreement, Annual Base Salary             $ 490,000
Separation Agreement, Salary Continuation   $ 490,000          
Separation Agreement, Salary Continuation, Term 10 months 12 months          
Separation Agreement, Salary Continuation, Percentage of Base Salary 50.00% 100.00%          
Separation Agreement, Reimbursement for Attorney Fees   $ 24,000          
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number   69,918          
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number   333,332          
Separation Agreement, Reimbursed Expenses, Per Hour   250          
Former Chief Executive Officer [Member] | Restricted Stock [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period   33,333          
Tc99m Tilmanocept License Agreement [Member]              
License Issue Fee       $ 25,000      
License Maintenance Fee       25,000      
Minimum Annual Royalty       $ 25,000      
Expanded Tc99m Tilmanocept License Agreement [Member] | License [Member]              
Research and development expenses         $ 101,409 $ 20,702  
Expanded Tc99m Tilmanocept License Agreement [Member] | Outside the Territory [Member] | License [Member]              
Cost of Goods and Services Sold, Total         868 4,339  
Amended and Restated Tilmanocept License Agreement [Member]              
License Issue Fee     $ 25,000        
License Maintenance Fee     25,000        
Minimum Annual Royalty     $ 25,000        
Research and development expenses         $ 25,000 $ 25,000